Novartis: failure of a study in lung cancer


(CercleFinance.com) – Novartis indicates that the phase III CANOPY-A study, evaluating canakinumab as an adjuvant treatment in non-small cell lung cancer, did not achieve its primary objective of progression-free survival in patients with stages II-IIIA and IIIB.

The Swiss health group specifies that no new safety signal has been observed, and that the data from this study, which involved 1,382 patients, will be presented at a future medical congress.

‘Each trial generates scientific evidence for research and development, and we will pursue new therapeutic options for patients living with lung cancer, whose needs remain urgent and significant.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85